Project Scope |
This Project team will create a White Paper with recommendations for Treatment Emergent Definitions, with a focus on Phase 2-4 clinical trials. This White Paper will build upon a White Paper that outlines results from a survey on current practices, indicating variation that can likely be reduced. Recommendations will be based on the desired end-in-mind, and may or may not be consistent with current practices. |
Project Leads | Emails |
---|---|
Mary Nilsson (Eli Lilly) | |
William Palo (, Abbvie) | |
Nicola Newton (, PHUSE , Project Assistant) |
| Working on a White PaperQ3 2024 | ||||||
---|---|---|---|---|---|---|---|
|
Objectives & Deliverables | Timelines |
---|
Project team review final White Paper
White Paper - Recommended Definition of Treatment-Emergent Adverse Events in Clinical Trials' | Q3 2024 |